Articles
Phasing forward with Seqens
Three custom development and manufacturing organizations – PCAS S.A. in France, Chemie Uetikon in Germany and PCI Synthesis in the United States –…
Read moreNewsroom
General / Research and Development
Flow chemistry for efficient and safe synthesis of APIs and intermediates
DOWNLOAD THE PRESS RELEASE Approximately 2,800 active pharmaceutical ingredients (APIs) are currently marketed, 70% of which being synthetic chemical molecules.Their…
Read more
API Manufacturing / General
API lifecycle management: A CDMO perspective
Didier Combis of Seqens CDMO explains why pharmaceutical companies should consider the specifics of the API when dealing with drug lifecycle management…
Read more
API Manufacturing / General
Developing Controlled Substances Requires a Whole New Level of Global Diligence
4 Best Practices For Taking the Right Precautions to Develop Safe and Effective controlled Substances By Laurent Alexandre, Director, Proprietary APIs, Seqens CDMO…
Read more
API Manufacturing / Articles / General
The Growth of the Generic Drug Marketplace
The Growth of the Generic Drug Marketplace: A Win-Win for Industry and Patients By Laurent Alexandre, Director, Proprietary APIs, Seqens CDMO Some…
Read more
API Manufacturing / Articles / General / Research and Development
Faster, Less Costly Cinacalcet Production is Among CDMO Responses to Alleviate Rising Cost of Drugs, Impact of Tariffs
Proprietary intermediates produced in Europe, U.S. rather than imported Across the world, the pressure to cut drug price costs has never been greater.
Read more
API Manufacturing
Deriving Value from Integrated cGMP and Pre-GMP Manufacturing Operations
Working with Contract Development & Manufacturing Organizations (CDMOs) in Asia has become a popular strategy for European and U.S.-based sponsors because of the associated…
Read more
General
SEQENS is committed to the development and production of critical molecules in France
SEQENS has decided to invest €65M to increase its development and production capacities for active ingredients and pharmaceutical intermediates and to accelerate…
Read more
API Manufacturing / General
A new large scale potent API manufacturing unit at SEQENS Villeneuve-La-Garenne
Shifting needs in the pharmaceutical market are driving a stronger demand for specialized production units to manufacture highly potent active…
Read more
General
Lahr’s Site: a Seqens CDMO plant.
Founded in 1991, The site of Lahr is part of SEQENS CDMO since mid-2015. The site is specialized in the development and manufacturing…
Read more
API Manufacturing / Articles / Press Releases / Research and Development
What kind of chemical structure will help the control of the most life-threatening side effects associated with CoVid-19- Some Salicylamide derivatives appears to be able to compete
DOWNLOAD THE PRESS RELEASE Gérard Guillamot SEQENS Scientific Director Due to the urgency of finding a treatment against CoVid-19,…
Read more
API Manufacturing / General
New warehouse for active ingredients (API’s) in Lahr
A new warehouse for active ingredients The production of active ingredients on site Lahr has increased steadily over the last years. It was…
Read more
API Manufacturing / Articles / General
The CDMO’s Challenges Developing An Oral Suspension For Children
By, Didier Combis, Commercial Director, Seqens CDMO; Christine Adam, Business Development Manager, Unither Pharmaceuticals and Jean Francois Cordoliani, Site Director, Unither Développement Bordeaux…
Read more
General
Why sponsors are turning to Western sources for regulatory starting materials (RSMs)
By Don LaFerle, Senior Vice President, Custom Synthesis, Seqens CDMO The ICH Q7 defines RSMs (Regulatory Starting Materials) as the point at…
Read more
API Manufacturing / General
Potent project
The Villeneuve-la-Garenne plant continues its transformation through the Potent project, which will enable the group to access the production of active pharmaceutical ingredients…
Read more